Haiyan E Liu, Meghah Vuppalapaty, Christian R Hoerner, Colin P Bergstrom, Michael Chiu, Clementine Lemaire, James Che, Amanpreet Kaur, Adam Dimmick, Sean Liu, Thomas J Metzner, Menna Araya, Steve Crouse, Markus Sprenger-Haussels, Martin Schlumpberger, John T Leppert, Siegfried Hauch, Elodie Sollier, Alice C Fan
BACKGROUND: Therapies for metastatic castration-resistant prostate cancer (mCRPC) include targeting the androgen receptor (AR) with androgen receptor inhibitors (ARIs) and prostate-specific membrane antigen (PSMA). Having the ability to detect AR, AR splice variant 7 (AR-V7), or PSMA in circulating tumor cells (CTCs) or circulating exosomal cell-free RNA (cfRNA) could be helpful to guide selection of the appropriate therapy for each individual patient. The Vortex Biosciences VTX-1 system is a label-free CTC isolation system that enables the detection of the expression of multiple genes in both CTCs and exosomal cfRNA from the same blood sample in patients with mCRPC...
April 16, 2024: BMC Cancer